Mycobacterium abscessus
SusceptibilityIn Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical IsolatesPulmonary disease due to infection with Mycobacterium abscessus complex (MABC) is notoriously difficult to treat, in large part due to the intrinsic resistance of MABC strains to most antibiotics, including β-lactams. MABC organisms express a broad-spectrum β-lactamase that is resistant to traditional β-lactam-based β-lactamase inhibitors but inhibited by a newer non-...
Experimental TherapeuticsRufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessusClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. This study identified another group of peptides, the rufomycins (RUFs), as bactericidal to M. tuberculosis...
Chemistry; BiosynthesisIndole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute InfectionNontuberculous mycobacteria (NTM) pathogens particularly infect patients with structural lung disorders. We previously reported novel indole-2-carboxamides (ICs) that are active against a wide panel of NTM pathogens.
Mechanisms of ResistanceMolecular Analysis of Linezolid-Resistant Clinical Isolates of Mycobacterium abscessusA total of 194 Mycobacterium abscessus isolates were collected from patients, and the whole genomes were sequenced. Eighty-five (43.8%) isolates showed linezolid (LZD) resistance.
Editor's Pick Mechanisms of ResistanceGenetic Correlation of Antibiotic Susceptibility and Resistance Genotyping for the Mycobacterium abscessus GroupTreatment efficacy of Mycobacterium abscessus infections depends on bacterial genotype. Here, the relationship between genotype, as determined by sequence analysis, and antibiotic resistance phenotype was analyzed.
Mechanisms of ResistanceMutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessusNew therapeutic approaches are needed against Mycobacterium abscessus, a respiratory mycobacterial pathogen that evades efforts to successfully treat infected patients. Clofazimine and bedaquiline, two drugs used for the treatment of multidrug-resistant tuberculosis, are being considered as alternatives for the treatment of lung diseases caused by...
Experimental TherapeuticsEffective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal CiprofloxacinNontuberculous mycobacteria (NTM) affect an increasing number of individuals worldwide. Infection with these organisms is more common in patients with chronic lung conditions, and treatment is challenging.
SusceptibilityMinocycline Has No Clear Role in the Treatment of Mycobacterium abscessus DiseaseMycobacterium abscessus causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment.
Clinical TherapeuticsNontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus ComplexMycobacterium avium complex (MAC) and M. abscessus complex (MABC) comprise the two most important human pathogen groups causing nontuberculous mycobacterial lung disease (NTM-LD). However, there are limited data regarding NTM-LD caused by mixed NTM infections.
- Experimental TherapeuticsScreening of Preselected Libraries Targeting Mycobacterium abscessus for Drug Discovery
Mycobacterium abscessus is intrinsically resistant to many antimycobacterial antibiotics, which presents serious problems in therapy. Here, we describe the development of a novel phenotype-based microscopic and computerized imaging drug screening approach.